Last updated 13 days ago
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
1530 patients around the world
Available in Brazil, Argentina
Merck Sharp & Dohme LLC
6Research sites
1530Patients around the world
This study is for people with
Breast Cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Av. Galvan 4102, CABA, Buenos Aireswww.cemic.edu.ar/
Perdriel 74, CABA, Buenos Aireshttps://www.hospitalbritanico.org.ar/
SponsorMerck Sharp & Dohme LLC
Conditions
Breast Cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06393374
